Home Newsfeeds Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

byBenzinga Newsdesk

January 11, 2023

1 minute read

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

Applied Digital Analysts Slash Their Forecasts After Q3 Results

By Avi Kapoor

April 12, 10:51 AM

Applied Digital Corporation (NASDAQ: APLD) reported worse-than-expected third-quarter financial results on Thursday.

APLD

AZZ Eyes Growth Spurt: Strong Markets Fuel FY25 Sales, Profit Forecast

By Lekha Gupta

April 8, 8:43 AM

AZZ raises FY25 guidance due to strength in several end markets. Sales outlook increased to $1.525-$1.625B, adjusted EPS to $4.50-$5.00, and adjusted EBITDA to $310-$360M. Company plans to report Q4 results on April 22, 2024.

AZZ

Amcon Distributing Q4 EPS $28.59 Up From $11.00 YoY

By Benzinga Newsdesk

November 23, 5:12 PM

Amcon Distributing (AMEX:DIT) reported quarterly earnings of $28.59 per share. This is a 159.91 percent increase over earnings of $11.00 per share from the same period last year.

DIT

What’s Going On With Baidu Stock Tuesday

By Anusuya Lahiri

June 20, 12:42 PM

Baidu, Inc (NYSE: BIDU) stock is trading higher Tuesday after Morgan Stanley analyst Gary Yu upgraded the stock from Equal-Weight to Overweight and raised the price target

BIDU

Guggenheim Downgrades Albireo Pharma to Neutral

Related Posts

Applied Digital Analysts Slash Their Forecasts After Q3 Results

AZZ Eyes Growth Spurt: Strong Markets Fuel FY25 Sales, Profit Forecast

Amcon Distributing Q4 EPS $28.59 Up From $11.00 YoY

What’s Going On With Baidu Stock Tuesday